BIOPHTA is a French preclinical-stage biotech company (FDA pre-IND) transforming ophthalmology to relieve patients in the treatment of their eye diseases. They develop a new standard of care to replace topical eye-drops as well as invasive intra-ocular injections for the retina.

Their technology is based on an innovative family of biopolymers that allow a one-week continuous treatment of the eye. They overcome efficacy issues of daily eyedrops as well as the high cost and invasiveness of ocular injections. It’s the first time a therapy displays such innovative technological features to disrupt both front-of-the-eye as well as retina treatments.

They improve the efficacy of eye treatments by leveraging the first 7-day continuous microdosing pharmaceutical form. This topical mucoadhesive ophthalmic insert is self-applied directly onto the eye surface by the patient and instantly jellifies. Their hydrogel strongly adheres to the eye surface for 7 days, allowing a one-week drug delivery to the eye of a controlled dose. It is the first topical and non-invasive therapy offering a continuous sustained release treatment of the retina.

–  Therapeutic areas: Ophthalmology, Glaucoma, Retina, Diabetic macular edema

–  Based in: Headquarter in Paris (FRANCE) Clinical operations based in Boston (MA)

–  Employees: 1 – 10

– Created in: 2020